Check out Takumi’s NEW English youtube channel🎵
↓↓↓
https://www.youtube.com/@takuway
https://vt.tiktok.com/ZSmrXCgo3/
What Happened (Core of the News)
Life Biosciences received IND clearance (authorization to begin clinical trials) from the U.S. FDA for its gene therapy “ER-100,” targeting optic nerve diseases.
This is not approval for general sale, but permission to begin human trials.
What the Therapy Aims to Do (Concept)
The goal is Partial Epigenetic Reprogramming — partially resetting cells in a more youthful direction.
Rather than changing the DNA sequence itself, the approach seeks to restore the epigenome (chemical markers that regulate gene ON/OFF states) to a younger configuration.
The “Three Genes” (Mechanism Overview)
The therapy uses three of the four Yamanaka factors:
OCT4 / SOX2 / KLF4 (OSK).Using all four carries tumor risk (especially due to c-Myc), so the design excludes the higher-risk factor and applies a partial, controlled reprogramming approach.
Why Start with the Eye? (Strategy)
Initial indications: Open-Angle Glaucoma (OAG) and NAION (a stroke-like optic nerve condition).
Local (intraocular) administration allows better risk management than systemic delivery.
Clinical endpoints (visual function) are measurable and trackable, making the eye strategically suitable for first-in-human studies.
What Is Claimed in Animal Studies (Preclinical Evidence)
According to Life Biosciences’ preclinical data:
Regeneration and improved visual function in optic nerve injury models
Visual function improvement in glaucoma models and naturally aged animals
Visual improvement in primate models
Reports such as “aged mice regained vision within weeks” have been explained in scientific commentary and background analyses
On “More Than Doubling Lifespan” (Caution Area)
Some reports mention lifespan extension in mice using related technologies. However, statements like “more than doubled lifespan” depend heavily on model and conditions and should not be generalized. The current FDA clearance focuses on optic nerve disease, and Phase 1’s primary objective is safety, not lifespan extension.
What Happens Next (Clinical Trial Roadmap)
Phase 1 (First-in-Human) will primarily evaluate:
Safety and tolerability
Immune response
Exploratory effects on visual function indicators
Whether this technology becomes transformative for humanity will depend on:
Human safety outcomes
Early signal data from these trials
↓↓↓Present↓↓↓Free seminar！
🌟
@megmeg979797
MEGUMI OHIGASHI｜Marketing & Mindset for Living Freely
https://www.instagram.com/megmeg979797?igsh=MWJ2Ym85eTU4dDU4Yw==
🔸LINE
https://iii-ho.com/i/jiyuu_insta/
_______________________________
↓↓↓PRESENT↓↓↓
@yuko_kiseki
YUKO☀️Miracle worker【Life's been a rollercoaster 5 times over🗻Mom of 4 kids including twins】
https://www.instagram.com/yuko_kiseki?igsh=OWxjb2NoYWVhOHo0&utm_source=qr
🔸LINE
When you send us the text “Present,”
we'll gift you a miracle-making present video and a 30-minute free consultation ticket 🎁✨
_______________________________
↓↓↓
At this time, in this era,
The flow is shifting all at once.
Live in your mission.
With the White Engine!!!
“A perspective where more people move not fueled by anxiety or comparison, but by their original motivation.” — Kako-san
https://www.instagram.com/kakochan_gram_/
↓↓↓
https://www.youtube.com/watch?v=kvN7Ozxdp04
〜〜〜
Your world is constructed by recognition.
We call this W1.
How do you set something outside of W1 (＝W2)?
W1 is built by your current recognition.
You set a goal outside of it — outside your recognition.
But if it’s outside your recognition, you cannot perceive it.
That is why the presence of a coach is required.
Even leadership no longer works well through teaching alone —
the power of coaching is now required.
However,
leaders are constrained by the intentions of those above them.
If they do not comply, they are not appointed.
Intent gets mixed into goal-setting.
That is no longer coaching — it becomes leading.
So how do you align
an individual’s desire
with the organization’s desire?
Professor Tomabechi
set the goal for W2 as 100% altruism (for the benefit of others).
↓↓↓
Let's research about Dr. Hideto Tomabechi！
↓↓↓
Open Chat "Dr. Hideto Tomabechi Study Group"
This is from quite a while ago, but please check it out too!
https://www.youtube.com/watch?v=h2xmUvKk0vA&t=1s
〜〜〜
This video features a discussion between cognitive scientists Dr. Hidetoshi Tomabechi and Takumi Yamazaki, explaining “the mindset for achieving goals beyond the current state” based on neuroscience and coaching theory.
https://movie.kamuin.com/entry/HEAVENSBELL-ASAGAYAINFO" target="_blank">
I was able to see the discussion between Sayoko-san and the director
up close,
and spend a wonderful evening in Asagaya. 映画情報 https://movie.kamuin.com/entry/HEAVENSBELL-ASAGAYAINFO
K
Link to Takumi Yamazaki’s
ENGLISH Book “SHIFT”